• Recruiting

NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM Multiple Myeloma

NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.


ARI0002h EHA2022

Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.


To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.


Sponsor

Sara V. Latorre


Collaborators

Fondos ARI (Assistencia Recerca Intensiva)

Instituto de Salud Carlos III

Fondo Social La Caixa

 

ClinicalTrials.gov Identifier: NCT04309981


Official Title: Pilot Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-BCMA (TNFRSF17) Specificity Humanized Conjugated With the Co-stimulatory Region 4-1BB and Signal-transduction CD3z (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma With Previous Treatment With Proteasome Inhibitor, Immunomodulatory Drug and Anti-CD38 Monoclonal Antibody


First Posted : March 17, 2020


Click here to see details on ClinicalTrials.gov


 

Biological: Adult differentiated autologous T-cells with anti-BCMA specificity


CARTBCMA-HCB-01

 

autologous differentiated anti-BCMA CAR T-cells ARI0002h


Differentiated Anti-BCMA Autologous CAR T Cells ARI0002h (Code C176769)

ARI 0002h

ARI-0002h

ARI0002h

Autologous Differentiated Anti-BCMA CAR T-cells ARI0002h

CARTBCMA ARI0002h

Differentiated Anti-BCMA Autologous CAR T Cells ARI0002h

 

J Immunother Cancer; 2021 Dec

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma


Click here for details

 

EHA 2022 Presentation

Type: Presidential Symposium

EHA 2022 - HYBRID - JUNE 9-17 - VIENNA


EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

We report the safety and efficacy results of the CARTBCMA-HCB-01 multicenter clinical trial for patients with relapsed/refractory multiple myeloma (RRMM) (NCT04309981) who received ARI0002h in 5 Spanish centers.


Click here to see Abstract details

 

EHA 2022 Presentation

Type: Poster presentation

EHA 2022 - HYBRID - JUNE 9-17 - VIENNA


SERUM MASS SPECTROMETRY TO ANALYZE DISEASE RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR T-CELL THERAPY


Click here to see Abstract details

 

Locations

Spain





Posts Archive